Schizophrenia is a devastating psychiatric condition that affects up to 1% of the US population. During the previous funding period, we reported that a loss of hippocampal interneuron function, recapitulates the hyperdopaminergic state thought to underlie psychosis in patients. In addition, we have recently provided one of the first reports describing the feasibility of interneuron transplants (derived from fetal medial ganglionic eminence) as a novel therapeutic approach for the treatment of schizophrenia. In these initial studies we focused primarily on the hyperdopaminergic state thought to underlie psychosis. In the present proposal, we will now address the issues of negative and cognitive deficits that are not only severely debilitating, but are not well treated by antipsychotic medications. Towards this end, we plan to examine the role of two separate interneuron populations, namely parvalbumin and somatostatin, in discrete but interconnected neuronal systems (the vHipp and mPFC) that likely underlie these symptoms clusters in schizophrenia. More broadly, this concept is central to understanding dimensions of behavior and neurobiological measures as detailed in the Research Domain Criteria project (RDoC). Taken together, the studies proposed will provide an understanding into the role of discrete interneuron populations in the pathophysiology of schizophrenia and will examine the utility of stem cell transplants as a potential treatment for this disease.

Public Health Relevance

Schizophrenia is a devastating psychiatric condition affecting up to 1% of the population. In this project we will investigate the role of discrete populations of inhibitory neurons in the pathogenesis of schizophrenia. In addition, we will examine whether stem cell transplants reverse physiological and behavioral deficits in a rodent model of schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH090067-06A1
Application #
9024375
Study Section
Special Emphasis Panel (ZRG1-MDCN-P (57))
Program Officer
Meinecke, Douglas L
Project Start
2010-07-01
Project End
2020-06-30
Budget Start
2015-09-25
Budget End
2016-06-30
Support Year
6
Fiscal Year
2015
Total Cost
$488,088
Indirect Cost
$149,886
Name
University of Texas Health Science Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Donegan, Jennifer J; Boley, Angela M; Lodge, Daniel J (2018) Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism. Neuropsychopharmacology 43:1789-1798
Perez, Stephanie M; Lodge, Daniel J (2018) Convergent Inputs from the Hippocampus and Thalamus to the Nucleus Accumbens Regulate Dopamine Neuron Activity. J Neurosci 38:10607-10618
Perez, Stephanie M; Donegan, Jennifer J; Boley, Angela M et al. (2018) Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat. Schizophr Res :
Aguilar, David D; Giuffrida, Andrea; Lodge, Daniel J (2018) Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility. Int J Neuropsychopharmacol 21:393-403
Neary, Jennifer L; Perez, Stephanie M; Peterson, Kara et al. (2017) Comparative analysis of MBD-seq and MeDIP-seq and estimation of gene expression changes in a rodent model of schizophrenia. Genomics 109:204-213
Carreno, Flavia R; Collins, Gregory T; Frazer, Alan et al. (2017) Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects. Int J Neuropsychopharmacol 20:504-509
Donegan, J J; Tyson, J A; Branch, S Y et al. (2017) Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model. Mol Psychiatry 22:1492-1501
Donegan, Jennifer J; Lodge, Daniel J (2017) Hippocampal Perineuronal Nets Are Required for the Sustained Antidepressant Effect of Ketamine. Int J Neuropsychopharmacol 20:354-358
Donegan, Jennifer J; Lodge, Daniel J (2017) Cell-based therapies for the treatment of schizophrenia. Brain Res 1655:262-269
Carreno, F R; Donegan, J J; Boley, A M et al. (2016) Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry 21:1298-308

Showing the most recent 10 out of 26 publications